13. The formulation as claimed in claim 11, wherein the polyol is selected from mannitol, sorbitol, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol and suitable combinations thereof preferably mannitol or sorbitol.
14. The formulation as claimed in claim 9, wherein the amino acid is present in the concentration of 0.1% to 10%.
15. The formulation as claimed in claim 1 which further comprises suitable excipients selected from surfactants.
16. The formulation as claimed in claim 15, wherein the surfactant is selected from polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers, alkylphenylpolyoxyethylene ethers, polyoxyethylene-polyoxypropylene copolymer and sodium dodecyl sulphate (SDS).
17. The formulation as claimed in claim 16, wherein the surfactant is selected from polysorbate 20 or polysorbate 80.
18. The formulation as claimed in claim 15, wherein the surfactant is 0.001 % to about 1 %.
19. A formulation as claimed in claim 1 comprising
    a) 1-160 mg / mL of adalimumab,
    b) 0.1-10% of stabilizer
    c) A buffer system with a pH of 4 to 8.
20. The formulation as claimed in claim 19, wherein the stabilizer is selected from sorbitol, raffinose, trehalose, arginine, lysine, glycine, mannitol, sucrose and combination thereof.
21. The formulation as claimed in claim 19,wherein the buffer is in the concentration of 1mM to about 100 mM, preferably 5 mM to 50 mM.
22. The formulation as claimed in claim 19, wherein the antibody concentration is 50 mg / mL.
23. The formulation as claimed in claim 19, which further comprises a surfactant wherein the surfactant is polysorbate 80 or polysorbate 20.
24. A lyophilized formulation comprising the composition as claimed in claim 1-23.
25. The formulation of claim 24 wherein the lyophilized powder is reconstituted with water.